130 related articles for article (PubMed ID: 9464661)
1. Effect of the cannabinoid receptor SPECT agent, AM 281, on hippocampal acetylcholine release from rat brain slices.
Gifford AN; Tang Y; Gatley SJ; Volkow ND; Lan R; Makriyannis A
Neurosci Lett; 1997 Nov; 238(1-2):84-6. PubMed ID: 9464661
[TBL] [Abstract][Full Text] [Related]
2. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A.
Gifford AN; Ashby CR
J Pharmacol Exp Ther; 1996 Jun; 277(3):1431-6. PubMed ID: 8667207
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of hippocampal acetylcholine release by cannabinoids: reversal by SR 141716A.
Gessa GL; Mascia MS; Casu MA; Carta G
Eur J Pharmacol; 1997 May; 327(1):R1-2. PubMed ID: 9185841
[TBL] [Abstract][Full Text] [Related]
4. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices.
Gifford AN; Samiian L; Gatley SJ; Ashby CR
Eur J Pharmacol; 1997 Apr; 324(2-3):187-92. PubMed ID: 9145770
[TBL] [Abstract][Full Text] [Related]
5. Large receptor reserve for cannabinoid actions in the central nervous system.
Gifford AN; Bruneus M; Gatley SJ; Lan R; Makriyannis A; Volkow ND
J Pharmacol Exp Ther; 1999 Feb; 288(2):478-83. PubMed ID: 9918548
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice.
Kathmann M; Weber B; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2001 Jan; 363(1):50-6. PubMed ID: 11191836
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoid receptor-mediated inhibition of acetylcholine release from hippocampal and cortical synaptosomes.
Gifford AN; Bruneus M; Gatley SJ; Volkow ND
Br J Pharmacol; 2000 Oct; 131(3):645-50. PubMed ID: 11015319
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A.
Gessa GL; Casu MA; Carta G; Mascia MS
Eur J Pharmacol; 1998 Aug; 355(2-3):119-24. PubMed ID: 9760025
[TBL] [Abstract][Full Text] [Related]
9. WIN-55,212-2 and SR-141716A alter nicotine-induced changes in locomotor activity, but do not alter nicotine-evoked [3H]dopamine release.
Rodvelt KR; Bumgarner DM; Putnam WC; Miller DK
Life Sci; 2007 Jan; 80(4):337-44. PubMed ID: 17067637
[TBL] [Abstract][Full Text] [Related]
10. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
11. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity.
Pan X; Ikeda SR; Lewis DL
Mol Pharmacol; 1998 Dec; 54(6):1064-72. PubMed ID: 9855635
[TBL] [Abstract][Full Text] [Related]
12. Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human.
Martin RS; Luong LA; Welsh NJ; Eglen RM; Martin GR; MacLennan SJ
Br J Pharmacol; 2000 Apr; 129(8):1707-15. PubMed ID: 10780977
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid CB1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in the brain.
Kathmann M; Bauer U; Schlicker E; Göthert M
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jun; 359(6):466-70. PubMed ID: 10431757
[TBL] [Abstract][Full Text] [Related]
14. Enhanced acetylcholine release in the hippocampus of cannabinoid CB(1) receptor-deficient mice.
Kathmann M; Weber B; Zimmer A; Schlicker E
Br J Pharmacol; 2001 Mar; 132(6):1169-73. PubMed ID: 11250865
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo.
Acquas E; Pisanu A; Marrocu P; Di Chiara G
Eur J Pharmacol; 2000 Aug; 401(2):179-85. PubMed ID: 10924924
[TBL] [Abstract][Full Text] [Related]
16. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices.
Maneuf YP; Brotchie JM
Br J Pharmacol; 1997 Apr; 120(8):1397-8. PubMed ID: 9113356
[TBL] [Abstract][Full Text] [Related]
18. Effects of 2-arachidonylglycerol, an endogenous cannabinoid, on neuronal activity in rat hippocampal slices.
Ameri A; Simmet T
Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):265-72. PubMed ID: 10731038
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse.
Mancinelli R; Fabrizi A; Del Monaco S; Azzena GB; Vargiu R; Colombo GC; Gessa GL
Life Sci; 2001 May; 69(1):101-11. PubMed ID: 11411800
[TBL] [Abstract][Full Text] [Related]
20. Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex.
Page ME; Oropeza VC; Van Bockstaele EJ
Neurosci Lett; 2008 Jan; 431(1):1-5. PubMed ID: 18055114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
